LTRN Q2 2024 Earnings — Lantern Pharma Inc. Revenue & Financial Results | Market Cap Arena

LTRNLantern Pharma Inc.

$31M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$5M

Net Income

-$5M

EPS (Diluted)

$-0.46

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$134,171

Balance Sheet

Total Assets

$36M

Total Liabilities

$5M

Stockholders' Equity

$31M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$5M	-$5M	-4.2%
Net Income	-$5M	-$5M	-4.5%